Background: In the Genes Environment Interaction in Respiratory Diseases population-based multi-case control study, we investigated whether asthma, chronic bronchitis (CB) and rhinitis were associated with a reduced 6-minute walk distance (6MWD), and whether the 6MWD determinants were similar for subjects with/without respiratory diseases. Methods: Cases of asthma (n = 360), CB (n = 120), rhinitis (n = 203) and controls (no respiratory diseases: n = 302) were recruited. The variation in the 6MWD across the groups was analyzed by ANCOVA, adjusting for gender, age, height, weight and comorbidity. The 6MWD determinants were studied by linear regression, and heterogeneity across the cases and controls was investigated. Results: The 6MWD differed across cases and controls (p = 0.01). It was shorter for cases of asthma (–17.1, 95% CI –28.3 to –5.8 m) and CB (–20.7, 95% CI: –36.6 to –4.8 m) than for controls (604 ± 68 m on average), but not for cases of rhinitis. The negative association between age and the 6MWD was significant for cases of CB, but not for the other groups (p = 0.001). Conclusions: Even at the level of severity found in the general population, asthma and CB could influence the 6MWD, which seems to reflect the functional exercise level for daily physical activities. The negative association between ageing and the 6MWD was particularly strong in subjects with CB. Our report adds to the mounting evidence that CB is not a trivial condition, especially in the ageing adult population, and it supports the importance of monitoring functional capacity and of physical reconditioning in mild asthma.

Keywords:
Functional exercise capacity, Six-minute walk test, Asthma, Chronic bronchitis
1.
Global Surveillance, Prevention and Control of Chronic Respiratory Diseases: A Comprehensive Approach. Geneva, World Health Organization, 2007.
2.
Cazzoletti L, Marcon A, Corsico A, Janson C, Jarvis D, Pin I, Accordini S, Bugiani M, Cerveri I, Gislason D, Gulsvik A, de Marco R: Asthma severity according to Global Initiative for Asthma and its determinants: an international study. Int Arch Allergy Immunol 2010;151:70–79.
3.
Reardon JZ, Lareau SC, ZuWallack R: Functional status and quality of life in chronic obstructive pulmonary disease. Am J Med 2006;119:32–37.
4.
Baiardini I, Braido F, Brandi S, Canonica GW: Allergic diseases and their impact on quality of life. Ann Allergy Asthma Immunol 2006;97:419–428.
5.
Satta A: Exercise training in asthma. J Sports Med Phys Fitness 2000;40:277–283.
6.
Ferré A, Fuhrman C, Zureik M, Chouaid C, Vergnenègre A, Huchon G, Delmas MC, Roche N: Chronic bronchitis in the general population: influence of age, gender and socio-economic conditions. Respir Med 2012;106:467–71.
7.
de Marco R, Accordini S, Cerveri I, Corsico A, Antó JM, Künzli N, Janson C, Sunyer J, Jarvis D, Chinn S, Vermeire P, Svanes C, Ackermann-Liebrich U, Gislason T, Heinrich J, Leynaert B, Neukirch F, Schouten JP, Wjst M, Burney P: Incidence of chronic obstructive pulmonary disease in a cohort of young adults according to the presence of chronic cough and phlegm. Am J Respir Crit Care Med 2007;175:32–39.
8.
American Thoracic Society Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories: Statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002;166:111–117.
9.
de Marco R, Accordini S, Antonicelli L, Bellia V, Bettin MD, Bombieri C, Bonifazi F, Bugiani M, Carosso A, Casali L, Cazzoletti L, Cerveri I, Corsico AG, Ferrari M, Fois AG, Lo Cascio V, Marcon A, Marinoni A, Olivieri M, Perbellini L, Pignatti P, Pirina P, Poli A, Rolla G, Trabetti E, Verlato G, Villani S, Zanolin ME, GEIRD Study Group: The Gene-Environment Interactions in Respiratory Diseases (GEIRD) Project. Int Arch Allergy Immunol 2010;152:255–263.
10.
de Marco R, Cappa V, Accordini S, Rava M, Antonicelli L, Bortolami O, Braggion M, Bugiani M, Casali L, Cazzoletti L, Cerveri I, Fois AG, Girardi P, Locatelli F, Marcon A, Marinoni A, Panico MG, Pirina P, Villani S, Zanolin ME, Verlato G, GEIRD Study Group: Trends in the prevalence of asthma and allergic rhinitis in Italy between 1991 and 2010. Eur Respir J 2012;39:883–892.
11.
American Thoracic Society: Standardization of spirometry, 1994 update. Am J Respir Crit Care Med 1995;152:1107–1136.
12.
Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC: Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J Suppl 1993;16:5–40.
13.
Chinn S, Burney P, Jarvis D, Luczynska C: Variation in bronchial responsiveness in the European Community Respiratory Health Survey (ECRHS). Eur Respir J 1997;10:2495–24501.
14.
Leng GC, Fowkes FG: The Edinburgh Claudication Questionnaire: an improved version of the WHO/Rose Questionnaire for use in epidemiological surveys. J Clin Epidemiol 1992;45:1101–1109.
15.
Cote CG, Casanova C, Marín JM, Lopez MV, Pinto-Plata V, de Oca MM, Dordelly LJ, Nekach H, Celli BR: Validation and comparison of reference equations for the 6-min walk distance test. Eur Respir J 2008;31:571–578.
16.
Gibbons WJ, Fruchter N, Sloan S, Levy RD: Reference values for a multiple repetition 6-minute walk test in healthy adults older than 20 years. J Cardiopulm Rehabil 2001;21:87–93.
17.
Enright PL, Sherrill DL: Reference equations for the six-minute walk in healthy adults. Am J Respir Crit Care Med 1998;158:1384–1387.
18.
Troosters T, Gosselink R, Decramer M: Six minute walking distance in healthy elderly subjects. Eur Respir J 1999;14:270–274.
19.
Chetta A, Zanini A, Pisi G, Aiello M, Tzani P, Neri M, Olivieri D: Reference values for the 6-min walk test in healthy subjects 20–50 years old. Respir Med 2006;100:1573–1578.
20.
Casanova C, Celli BR, Barria P, Casas A, Cote C, de Torres JP, Jardim J, Lopez MV, Marin JM, Montes de Oca M, Pinto-Plata V, Aguirre-Jaime A: Six Minute Walk Distance Project (ALAT). The 6-min walk distance in healthy subjects: reference standards from seven countries. Eur Respir J 2011;37:150–156.
21.
Sciurba F, Criner GJ, Lee SM, Mohsenifar Z, Shade D, Slivka W, Wise RA, National Emphysema Treatment Trial Research Group: Six-minute walk distance in chronic obstructive pulmonary disease: reproducibility and effect of walking course layout and length. Am J Respir Crit Care Med 2003;167:1522–1527.
22.
Hill K, Goldstein RS: Limited functional performance in chronic obstructive pulmonary disease: nature, causes and measurement. COPD 2007;4:257–261.
23.
Eisner MD, Blanc PD, Yelin EH, Sidney S, Katz PP, Ackerson L, Lathon P, Tolstykh I, Omachi T, Byl N, Iribarren C: COPD as a systemic disease: impact on physical functional limitations. Am J Med 2008;121:789–796.
24.
Ritz T, Rosenfield D, Steptoe A: Physical activity, lung function, and shortness of breath in the daily life of individuals with asthma. Chest 2010;138:913–918.
25.
Stauder A, Kovács M: Anxiety symptoms in allergic patients: identification and risk factors. Psychosom Med 2003;65:816–823.
26.
Mancuso CA, Sayles W, Robbins L, Phillips EG, Ravenell K, Duffy C, Wenderoth S, Charlson ME: Barriers and facilitators to healthy physical activity in asthma patients. J Asthma 2006;43:137–143.
27.
van Manen JG, Bindels PJ, Dekker FW, IJzermans CJ, van der Zee JS, Schadé E: Risk of depression in patients with chronic obstructive pulmonary disease and its determinants. Thorax 2002;57:412–416.
28.
Butcher SJ, Meshke JM, Sheppard MS: Reductions in functional balance, coordination, and mobility measures among patients with stable chronic obstructive pulmonary disease. J Cardiopulm Rehabil 2004;24:274–280.
29.
Garcia-Aymerich J, Serra Pons I, Mannino DM, Maas AK, Miller DP, Davis KJ: Lung function impairment, COPD hospitalisations and subsequent mortality. Thorax 2011;66:585–590.
30.
Kanervisto M, Saarelainen S, Vasankari T, Jousilahti P, Heistaro S, Heliövaara M, Luukkaala T, Paavilainen E: COPD, chronic bronchitis and capacity for day-to-day activities: negative impact of illness on the health-related quality of life. Chron Respir Dis 2010;7:207–215.
31.
Puhan MA, Mador MJ, Held U, Goldstein R, Guyatt GH, Schünemann HJ: Interpretation of treatment changes in 6-minute walk distance in patients with COPD. Eur Respir J 2008;32:637–643.
32.
Troosters T: How important is a minimal difference? Eur Respir J 2011;37:755–756.
33.
Redelmeier DA, Bayoumi AM, Goldstein RS, Guyatt GH: Interpreting small differences in functional status: the six minute walk test in chronic lung disease patients. Am J Respir Crit Care Med 1997;155:1278–1282.
34.
Puhan MA, Chandra D, Mosenifar Z, Ries A, Make B, Hansel NN, Wise RA, Sciurba F, National Emphysema Treatment Trial (NETT) Research Group: The minimal important difference of exercise tests in severe COPD. Eur Respir J 2011;37:784–790.
35.
Ito K, Barnes PJ: COPD as a disease of accelerated lung aging. Chest 2009;135:173–180.
36.
Dexter T: Relationship between sport knowledge, sport performance and academic ability: empirical evidence from GCSE Physical Education. General Certificate of Secondary Education. J Sports Sci 1999;17:283–295.
37.
Parizkova J: Impact of education on food behaviour, body composition and physical fitness in children. Br J Nutr 2008;99:S26–S32.
38.
Unverdorben M, Mostert A, Munjal S, van der Bijl A, Potgieter L, Venter C, Liang Q, Meyer B, Roethig HJ: Acute effects of cigarette smoking on pulmonary function. Regul Toxicol Pharmacol 2010;57:241–246.
39.
Sin DD, Jones RL, Mannino DM, Paul Man SF: Forced expiratory volume in 1 second and physical activity in the general population. Am J Med 2004;117:270–273.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.